Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological therapeutic effects of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma

Goto,Shintaro; Yoshizawa,Tadashi; Ishido,Keinosuke; Seino,Hiroko; Morohashi,Satoko; Ogasawara,Hirokazu; Kubota,Shunsuke; Ogasawara,Kenta; Nakamura,Akie; Hakamada,Kenichi; Kijima,Hiroshi

doi:10.3892/or.2023.8498

Use of time‑density curves of dynamic contrast‑enhanced computed tomography for determination of the histological therapeutic effects of neoadjuvant chemotherapy for pancreatic ductal adenocarcinoma

Authors:
- Shintaro Goto
- Tadashi Yoshizawa
- Keinosuke Ishido
- Hiroko Seino
- Satoko Morohashi
- Hirokazu Ogasawara
- Shunsuke Kubota
- Kenta Ogasawara
- Akie Nakamura
- Kenichi Hakamada
- Hiroshi Kijima
View Affiliations

Affiliations: Department of Pathology and Bioscience, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan, Department of Gastroenterological Surgery, Hirosaki University Graduate School of Medicine, Hirosaki, Aomori 036‑8562, Japan, Department of Radiology, Aomori National Hospital, Namioka, Aomori 038‑1338, Japan
Published online on: February 13, 2023 https://doi.org/10.3892/or.2023.8498
Article Number: 61
Copyright: © Goto et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the histological changes caused by neoadjuvant chemotherapy (NAC) for pancreatic ductal adenocarcinoma (PDAC), and to demonstrate the use of time‑density curves (TDCs) of dynamic contrast‑enhanced computed tomography (CECT) for determination of the histological therapeutic effects of NAC for PDAC. A total of 96 patients with PDAC were examined; 46 underwent NAC (NAC group) and 50 did not undergo NAC (non‑NAC group). Based on histological therapeutic effect and using the area of residual tumor (ART) grading system, the NAC group was divided into low‑responders and high‑responders. Histological analysis was used to evaluate the densities of cancer cells, cancer‑associated fibroblasts (CAFs), microvessels and stromal collagen fibers in the NAC and non‑NAC groups. Radiological analysis was used to evaluate the TDCs of three slopes of the NAC group, namely slopes between the non‑contrast and arterial phases (δ1 and δ1'), between the arterial and portal phases (δ2 and δ2'), and between the portal and equilibrium phases (δ3 and δ3'). δ1‑δ3 were before NAC, whereas δ1'‑δ3' were after NAC. Changes in δ1, δ2 and δ3 before and after NAC were denoted as δδ1 (=δ1'‑δ1), δδ2 (=δ2'‑δ2) and δδ3 (=δ3'‑δ3). ART grading system, histological examination and radiological examination data were also statistically analyzed. Histological examination revealed a significant decrease in cancer cells and CAFs, and a significant increase in stromal collagen fibers due to NAC (P<0.01). Radiological examination revealed that δ1' was significantly higher than δ1 in low‑responders (P<0.05), whereas δ2' was significantly lower than δ2 in high‑responders (P<0.01). δδ2 was significantly lower and δδ3 was significantly higher in high‑responders than in low‑responders (P<0.01 and P<0.05, respectively). Receiver operating characteristic curve showed that δδ2 and δδ3 were effective indicators of the histological therapeutic effect of NAC. In conclusion, the TDC of dynamic CECT may be useful for determining the histological therapeutic effect of NAC for PDAC.

View Figures

View References

1	Burris HA III, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, et al: Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial. J Clin Oncol. 15:2403–2413. 1997. View Article : Google Scholar : PubMed/NCBI
2	Whatcott CJ, Diep CH, Jiang P, Watanabe A, LoBello J, Sima C, Hostetter G, Shepard HM, Von Hoff DD and Han H: Desmoplasia in primary tumors and metastatic lesions of pancreatic cancer. Clin Cancer Res. 21:3561–3568. 2015. View Article : Google Scholar : PubMed/NCBI
3	Neesse A, Bauer CA, Öhlund D, Lauth M, Buchholz M, Michl P, Tuveson DA and Gress TM: Stromal biology and therapy in pancreatic cancer: Ready for clinical translation? Gut. 68:159–171. 2019. View Article : Google Scholar : PubMed/NCBI
4	Oba A, Ho F, Bao QR, Al-Musawi MH, Schulick RD and Del Chiaro M: Neoadjuvant treatment in pancreatic cancer. Front Oncol. 10:2452020. View Article : Google Scholar : PubMed/NCBI
5	Motoi F and Unno M: Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. Jpn J Clin Oncol. 50:483–489. 2020. View Article : Google Scholar : PubMed/NCBI
6	Versteijne E, van Dam JL, Suker M, Janssen QP, Groothuis K, Akkermans-Vogelaar JM, Besselink MG, Bonsing BA, Buijsen J, Busch OR, et al: Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: Long-term results of the Dutch randomized PREOPANC trial. J Clin Oncol. 40:1220–1230. 2022. View Article : Google Scholar : PubMed/NCBI
7	Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al: Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 369:1691–1703. 2013. View Article : Google Scholar : PubMed/NCBI
8	Goldstein D, El-Maraghi RH, Hammel P, Heinemann V, Kunzmann V, Sastre J, Scheithauer W, Siena S, Tabernero J, Teixeira L, et al: nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Long-term survival from a phase III trial. J Natl Cancer Inst. 107:dju4132015. View Article : Google Scholar : PubMed/NCBI
9	Welsh JL, Bodeker K, Fallon E, Bhatia SK, Buatti JM and Cullen JJ: Comparison of response evaluation criteria in solid tumors with volumetric measurements for estimation of tumor burden in pancreatic adenocarcinoma and hepatocellular carcinoma. Am J Surg. 204:580–585. 2012. View Article : Google Scholar : PubMed/NCBI
10	Chatterjee D, Katz MH, Rashid A, Wang H, Iuga AC, Varadhachary GR, Wolff RA, Lee JE, Pisters PW, Crane CH, et al: Perineural and intraneural invasion in posttherapy pancreaticoduodenectomy specimens predicts poor prognosis in patients with pancreatic ductal adenocarcinoma. Am J Surg Pathol. 36:409–417. 2012. View Article : Google Scholar : PubMed/NCBI
11	Lee SM, Katz MH, Liu L, Sundar M, Wang H, Varadhachary GR, Wolff RA, Lee JE, Maitra A, Fleming JB, et al: Validation of a proposed tumor regression grading scheme for pancreatic ductal adenocarcinoma after neoadjuvant therapy as a prognostic indicator for survival. Am J Surg Pathol. 40:1653–1660. 2016. View Article : Google Scholar : PubMed/NCBI
12	Kalimuthu SN, Serra S, Dhani N, Hafezi-Bakhtiari S, Szentgyorgyi E, Vajpeyi R and Chetty R: Regression grading in neoadjuvant treated pancreatic cancer: An interobserver study. J Clin Pathol. 70:237–243. 2017. View Article : Google Scholar : PubMed/NCBI
13	Matsuda Y, Ohkubo S, Nakano-Narusawa Y, Fukumura Y, Hirabayashi K, Yamaguchi H, Sahara Y, Kawanishi A, Takahashi S, Arai T, et al: Objective assessment of tumor regression in post-neoadjuvant therapy resections for pancreatic ductal adenocarcinoma: Comparison of multiple tumor regression grading systems. Sci Rep. 10:182782020. View Article : Google Scholar : PubMed/NCBI
14	Ferrone CR, Marchegiani G, Hong TS, Ryan DP, Deshpande V, McDonnell EI, Sabbatino F, Santos DD, Allen JN, Blaszkowsky LS, et al: Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 261:12–17. 2015. View Article : Google Scholar : PubMed/NCBI
15	Wagner M, Antunes C, Pietrasz D, Cassinotto C, Zappa M, Sa Cunha A, Lucidarme O and Bachet JB: CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol. 27:3104–3116. 2017. View Article : Google Scholar : PubMed/NCBI
16	Goto S, Seino H, Yoshizawa T, Morohashi S, Ishido K, Hakamada K and Kijima H: Time density curve of dynamic contrast-enhanced computed tomography correlates with histological characteristics of pancreatic cancer. Oncol Lett. 21:2762021. View Article : Google Scholar : PubMed/NCBI
17	Brierley JD, Gospodarowicz MK and Wittekind C: The TNM classification of malignant tumours. 8th edition. Wiley-Blackwell; Oxford: pp. 93–95. 2017
18	WHO Classification of Tumours Editorial Board, . WHO classification of tumours of the digestive system. IARC Press; Lyon: pp. 322–332. 2019
19	Inoue C, Miki Y, Saito R, Hata S, Abe J, Sato I, Okada Y and Sasano H: PD-L1 induction by cancer-associated fibroblast-derived factors in lung adenocarcinoma cells. Cancers (Basel). 11:12572019. View Article : Google Scholar : PubMed/NCBI
20	Itou RA, Uyama N, Hirota S, Kawada N, Wu S, Miyashita S, Nakamura I, Suzumura K, Sueoka H, Okada T, et al: Immunohistochemical characterization of cancer-associated fibroblasts at the primary sites and in the metastatic lymph nodes of human intrahepatic cholangiocarcinoma. Hum Pathol. 83:77–89. 2019. View Article : Google Scholar : PubMed/NCBI
21	Zhang J, Li S, Zhao Y, Ma P, Cao Y, Liu C, Zhang X, Wang W, Chen L and Li Y: Cancer-associated fibroblasts promote the migration and invasion of gastric cancer cells via activating IL-17a/JAK2/STAT3 signaling. Ann Transl Med. 8:8772020. View Article : Google Scholar : PubMed/NCBI
22	Matsuda K, Ohga N, Hida Y, Muraki C, Tsuchiya K, Kurosu T, Akino T, Shih SC, Totsuka Y, Klagsbrun M, et al: Isolated tumor endothelial cells maintain specific character during long-term culture. Biochem Biophys Res Commun. 394:947–954. 2010. View Article : Google Scholar : PubMed/NCBI
23	Calvi EN, Nahas FX, Barbosa MV, Calil JA, Ihara SS, Silva Mde S, Franco MF and Ferreira LM: An experimental model for the study of collagen fibers in skeletal muscle. Acta Cir Bras. 27:681–686. 2012. View Article : Google Scholar : PubMed/NCBI
24	Kanda Y: Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48:452–458. 2013. View Article : Google Scholar : PubMed/NCBI
25	Miyashita T, Tajima H, Makino I, Okazaki M, Yamaguchi T, Ohbatake Y, Nakanuma S, Hayashi H, Takamura H, Ninomiya I, et al: Neoadjuvant chemotherapy with gemcitabine plus nab-paclitaxel reduces the number of cancer-associated fibroblasts through depletion of pancreatic stroma. Anticancer Res. 38:337–343. 2018.PubMed/NCBI
26	Mancini ML and Sonis ST: Mechanisms of cellular fibrosis associated with cancer regimen-related toxicities. Front Pharmacol. 5:512014. View Article : Google Scholar : PubMed/NCBI
27	Arimoto A, Uehara K, Tsuzuki T, Aiba T, Ebata T and Nagino M: Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer. Int J Clin Oncol. 20:935–942. 2015. View Article : Google Scholar : PubMed/NCBI
28	Eefsen RL, Engelholm L, Willemoe GL, Van den Eynden GG, Laerum OD, Christensen IJ, Rolff HC, Høyer-Hansen G, Osterlind K, Vainer B and Illemann M: Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab. Int J Cancer. 138:1777–1784. 2016. View Article : Google Scholar : PubMed/NCBI
29	Awai K and Date S: Basic knowledge to achieve optimal enhancement of CT. Nichidoku Iho. 56:13–32. 2011.
30	Harder FN, Jungmann F, Kaissis GA, Lohöfer FK, Ziegelmayer S, Havel D, Quante M, Reichert M, Schmid RM, Demir IE, et al: [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Res. 11:702021. View Article : Google Scholar : PubMed/NCBI
31	Hamdy A, Ichikawa Y, Toyomasu Y, Nagata M, Nagasawa N, Nomoto Y, Sami H and Sakuma H: Perfusion CT to assess response to neoadjuvant chemotherapy and radiation therapy in pancreatic ductal adenocarcinoma: Initial experience. Radiology. 292:628–635. 2019. View Article : Google Scholar : PubMed/NCBI
32	Abdelrahman AM, Goenka AH, Alva-Ruiz R, Yonkus JA, Leiting JL, Graham RP, Merrell KW, Thiels CA, Hallemeier CL, Warner SG, et al: FDG-PET predicts neoadjuvant therapy response and survival in borderline resectable/locally advanced pancreatic adenocarcinoma. J Natl Compr Canc Netw. 20:1023–1032.e3. 2022. View Article : Google Scholar : PubMed/NCBI
33	Koay EJ, Truty MJ, Cristini V, Thomas RM, Chen R, Chatterjee D, Kang Y, Bhosale PR, Tamm EP, Crane CH, et al: Transport properties of pancreatic cancer describe gemcitabine delivery and response. J Clin Invest. 124:1525–1536. 2014. View Article : Google Scholar : PubMed/NCBI
34	Myllyharju J and Kivirikko KI: Collagens and collagen-related diseases. Ann Med. 33:7–21. 2001. View Article : Google Scholar : PubMed/NCBI